Ingeborg Lues
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ingeborg Lues.
European Journal of Medicinal Chemistry | 1993
Rochus Jonas; Michael Klockow; Ingeborg Lues; H Prücher; Hj Schliep; H Wurziger
Abstract The synthesis of new heterocyclic benzimidazolo-pyridazinones is described. The new compounds were evaluated as inotropic agents with ‘calcium-sensitizing’ effects. 5-Methyl-6-[2-(3-pyrazolyl)-5-benzimidazolyl]-2,3,4,5-tetrahydro-pyridazin-3-one hydrochloride (meribendan) turned out to be the most interesting compound and was chosen for development as a positive inotrope.
Bioorganic & Medicinal Chemistry Letters | 1992
Rochus Jonas; Michael Klockow; Ingeborg Lues
Abstract Both enantiomers of EMD 53 998 (1), a novel cardiotonic with Ca-sensitizing activity, were readily prepared by kinetic resolution of the N-acylthiadiazinone 2. The Ca-sensitizing effect is highly stereospecific and resides in the (+)-enantiomer. The (−)-entantiomer is a pure PDE inhibitor devoid of any Ca-sensitizing activity.
Bioorganic & Medicinal Chemistry Letters | 1994
Mathias Osswald; Werner Mederski; Michael Schwarz; Norbert Beier; Ingeborg Lues; Klaus-Otto Dr. Minck
Abstract The syntheses and biological activities of a series of novel 3-substituted 6-butyl-1,2-dihydro-pyridin-2-ones are presented. A number of these compounds are shown to be potent antagonists of angiotensin II with in vitro potencies in the nanomolar or even subnanomolar range. They also have proven their suitability as effective inhibitors of angiotensin II pressor response in vivo.
Bioorganic & Medicinal Chemistry Letters | 1994
Rochus Jonas; Michael Klockow; Ingeborg Lues; H Wurziger
Abstract In 5-methyl-dihydropyridazinones, a stereoselectivity is observed only with respect to the phosphodiesterase III-inhibition. The (−)-enantiomers are very strong inhibitors whereas their (+)-counterparts exhibit only a weak activity. In the case of the thiadiazinone EMD 53998 a pronounced stereoselectivity regarding Ca-sensitivity and phosphodiesterase inhibition is apparent. It is concluded that Levosimendan exerts its positive inotropism almost exclusively through its potent phosphodiesterase III-inhibitory effect.
Pflügers Archiv: European Journal of Physiology | 1989
J.-E. de Peyer; Ingeborg Lues; Rolf Gericke; G. Häusler
Introduction Recent publication have indicated that some benzopyran derivatives (e.g. cromakalim) are potent relaxants of a number of smooth muscles. Their main pharmacological properties are most probably related to their ability to hyperpolarize the membranes of smooth muscle cells by increasing the conductance to potassium ions (Hamilton et al. 1986). We have therefore explored the possibility that a newly synthetised derivative, EMD 52692 (4-(1,2-dihydro-2-oxo1 -pyridyl)-2,2-dimethyl-2H1-benzo pyran-6-carbonitrile), also induces vascular relaxation by a similar mechanism.
Archive | 1992
Werner Dr. Mederski; Norbert Beier; Pierre Schelling; Ingeborg Lues; Klaus-Otto Dr. Minck
Archive | 1994
Dieter Dorsch; Werner Mederski; Mathias Osswald; Pierre Schelling; Norbert Beier; Ingeborg Lues; Klaus-Otto Dr. Minck
Journal of Medicinal Chemistry | 1994
Werner Mederski; Dieter Dorsch; Heinz-Hermann Bokel; Norbert Beier; Ingeborg Lues; Pierre Schelling
Archive | 1995
Rolf Gericke; Manfred Baumgarth; Dieter Dorsch; Norbert Beier; Klaus-Otto Dr. Minck; Ingeborg Lues
Archive | 1993
Werner Mederski; Norbert Beier; Pierre Schelling; Ingeborg Lues; Klaus-Otto Dr. Minck